GoodRx Holdings, Inc. Class A (GDRX)

Over the past six months, GoodRx Holdings, Inc. stock has experienced several notable events and analyst activities. The stock's 52-week range has been between $2.10 and $5.81, with a year-over-year change of -49.59%. As of February 5, 2026, the closing stock price was $2.29. In Q3 2025, GoodRx reported earnings per share of $0.08, surpassing analysts' expectations by 14.29%. Barclays initiated coverage with an "Underweight" rating, while Morgan Stanley maintained an "Equal-Weight" recommendation. GoodRx launched RxSmartSaver at Giant Eagle Pharmacies and is powering pricing for leading brand medications on TrumpRx. GoodRx earned HITRUST i1 Certification for the second consecutive year. GoodRx revised its revenue growth expectations for 2024 to a mid-single-digit percentage.

GoodRx's revenue growth expectations for 2024 have been supported by increased utilization from seasonal factors, suggesting that there is some seasonality in the demand for GoodRx's products and services, with certain periods experiencing higher utilization.

GoodRx Holdings, Inc. is an American healthcare company operating a consumer-focused digital healthcare platform in the United States, with the mission to reduce healthcare costs and enhance accessibility to medications and healthcare services. The company operates within the Health Services sector and is categorized under the Medical/Nursing Services and Information Services (B2C) industries. GoodRx provides a price comparison platform, drug coupons and discount programs, telehealth services, pharma manufacturer solutions, and subscription services.

GoodRx Holdings, Inc. primarily operates within the United States, comparing prescription drug prices at over 75,000 pharmacies across the country. The company is headquartered in Santa Monica, California.

GoodRx has a strong brand reputation as a prominent player in the digital healthcare space, recognized for providing affordable healthcare solutions and significant savings to consumers. The company's platform processes over 360 billion pricing data points daily and is SOC2 certified. However, the company's reputation can be impacted by regulatory and legal risks, including data protection, privacy, and advertising laws. The company has faced the risk of litigation, such as for unauthorized text messages, which could materially affect its business.

GoodRx Holdings, Inc. has a significant institutional ownership presence, with 247 institutional owners and shareholders holding 121,545,269 shares, representing 62.83% institutional ownership and 12.67% insider ownership. Major institutional owners include Francisco Partners Management, LP, Vanguard Group Inc, and Ameriprise Financial Inc. The largest individual/private company shareholders include Francisco Partners Management, L.P. (18% of shares outstanding) and Idea Men, LLC (13% of shares outstanding).